Page 31 - Demo

31enero-abril 2024 Frontera Biotecnol%u00f3gica | N%u00b0 27 Las terapias g%u00e9nicas prometen curar una enfermedad a una %u00fanica dosis y se han logrado desarrollar varias para tratar diversas enfermedades, principalmente c%u00e1ncer y enfermedades raras. Actualmente, se cuenta con decenas de terapias g%u00e9nicas aprobadas, sin embargo, se aplican principalmente en pa%u00edses desarrollados y algunas han sido retiradas del mercado o no son cubiertas por los sistemas de salud p%u00fablica debido a su alto costo. De hecho, los an%u00e1lisis de impacto presupuestal de estas terapias muestran que su carga econ%u00f3mica es considerable y que, para poder pagarlas, sus sistemas de salud deber%u00edan negociar planes de pago con los productores, como lo son los pagos por anualidades o incluso pagos basados en rendimiento. A pesar de los avances en el desarrollo de estas terapias, es evidente que su acceso al p%u00fablico es a%u00fan muy complicado, incluso para aquellos pa%u00edses de altos ingresos que ya han logrado pagarlas.Palabras clave: Terapias g%u00e9nicas, impacto presupuestal, sistemas de salud, planes de pago.Gene therapies promise to cure a disease with a single dose and several have been developed to treat various diseases, mainly cancer and rare diseases. Currently, there are dozens of approved gene therapies, however, they are mainly applied in developed countries and some have been withdrawn from the market or are not covered by public health systems due to their high cost. In fact, budget impact analyzes of these therapies show that their economic burden is considerable and that, in order to pay for them, their health systems should negotiate payment plans with producers, such as annual payments or even performance-based payments. Despite advances in these therapies, it is evident that their access to the public is still very complicated, even for those countries that have managed to pay for them.Keywords: Gene therapies, budget impact, healthcare system, payment plansRESUMENABSTRACTISSN: 2448-8461